When a gout attack strikes, the pain is driven not just by uric acid crystals lodging in a joint — it's driven by the inflammatory cascade those crystals ignite. PRKG2 encodes cGMP-dependent protein kinase II (cGKII)¹¹ cGMP-dependent protein kinase II (cGKII)
a serine/threonine kinase activated by cyclic GMP, expressed in intestinal epithelium, kidney, cartilage, and immune cells, a signaling enzyme that turns out to sit at a key amplification point in this cascade. The intronic variant rs6837293 was identified as a possible gout-susceptibility locus in a Taiwanese genome-wide analysis — but replication has been elusive, leaving its clinical significance unsettled.

The Mechanism

cGKII phosphorylates the CFTR chloride channel in intestinal epithelium, regulates renin secretion in the kidney, and supports endochondral bone growth — but its most relevant role for gout is in immune cells. A 2015 study by Zhou et al.²² A 2015 study by Zhou et al.
Zhou et al. Cyclic GMP-dependent protein kinase II is necessary for macrophage M1 polarization and phagocytosis via toll-like receptor 2. J Mol Med, 2015 demonstrated that cGKII expression is high in M1-polarized macrophages (the pro-inflammatory phenotype) but low in M2 (anti-inflammatory) macrophages. When scientists silenced cGKII, M1 activation was significantly reduced. Critically, when macrophages were exposed to monosodium urate (MSU) crystals — the trigger of gout attacks — cGKII and toll-like receptor 2 (TLR2) expression both increased, amplifying M1 polarization and phagocytic activity. Knocking down cGKII blunted the MSU-induced inflammatory response.

This positions PRKG2 as an inflammation amplifier in gout: variants that alter cGKII expression or activity could modulate how intensely the innate immune system responds to urate crystals. The intronic location of rs6837293 suggests a regulatory rather than coding mechanism — potentially affecting PRKG2 expression levels in relevant tissues.

The Evidence

Initial discovery — Taiwanese population: Chang et al. 2009³³ Chang et al. 2009
Chang SJ et al. The cyclic GMP-dependent protein kinase II gene associates with gout disease: identified by genome-wide analysis and case-control study. Ann Rheum Dis, 2009 identified PRKG2 through a genome-wide analysis in 8 gout patients and 10 unaffected relatives, then validated in a case-control study of 74 male gout patients and 74 age-matched healthy controls from a Taiwanese population. Both rs6837293 and rs7688672 showed significant association with gout under a recessive model (rs6837293 OR = 2.72, 95% CI 1.13–6.54; rs7688672 OR = 2.89, 95% CI 1.19–7.02), and the association remained after adjusting for serum uric acid levels — suggesting that PRKG2 may influence gout risk through the inflammatory response to crystals rather than through urate concentration alone.

Replication failure — Japanese population: Sakiyama et al. 2014⁴⁴ Sakiyama et al. 2014
Sakiyama M et al. Common variants of cGKII/PRKG2 are not associated with gout susceptibility. J Rheumatol, 2014 attempted replication in a substantially larger Japanese cohort: 741 male gout patients and 1,302 controls. All four PRKG2 variants — including rs6837293 — showed no association with gout in any genetic model (allele frequency, dominant, or recessive). The authors concluded that cGKII is not involved in gout susceptibility.

Mixed results — Chinese cohort: Guo et al. 2015⁵⁵ Guo et al. 2015
Guo M et al. Polymorphism of rs7688672 and rs10033237 in cGKII/PRKG2 and gout susceptibility of Han population in northern China. Gene, 2015 tested different PRKG2 variants in 405 gout cases and 429 controls (Han Chinese), finding rs10033237 associated with gout but rs7688672 not — further highlighting the inconsistency of PRKG2 findings across populations and variant sets.

Taken together, the evidence for rs6837293 is emerging at best. The original study was small (74 cases), and the larger replication failed. The biological mechanism — cGKII amplifying urate crystal inflammation — is plausible and supported by in vitro data, but the specific role of this intronic variant remains unestablished.

Practical Actions

For TT homozygotes, the empirical gout-susceptibility signal (even if fragile) points toward the inflammatory arm of gout rather than the urate-production arm. This means standard urate-lowering dietary measures are still relevant but may need to be paired with attention to foods and supplements that modulate innate immune activation.

Limiting dietary purines (organ meats, shellfish, red meat, alcohol — especially beer and spirits) reduces urate substrate and therefore crystal formation risk regardless of PRKG2 genotype. If cGKII does amplify the inflammatory response to existing crystals, maintaining serum urate well below the crystallisation threshold of 6.8 mg/dL becomes more important for TT carriers than for CC carriers.

Serum uric acid monitoring is the most actionable next step — a fasting uric acid test can stratify actual hyperuricemia risk, which is the prerequisite for crystal formation regardless of downstream inflammatory gene variants.

Interactions

With SLC2A9 rs3733591 and ABCG2 rs2231142: SLC2A9 and ABCG2 are the strongest determinants of serum urate concentration (explaining ~5% of variance each). PRKG2, if genuinely involved in gout susceptibility, would represent a downstream effector operating after crystal formation — meaning the combination of high-urate genotypes (SLC2A9 C/C, ABCG2 T/T) plus the proposed PRKG2 rs6837293 TT genotype might confer both elevated crystal burden and an amplified inflammatory response, though no study has examined this combination directly.

With rs7688672 (PRKG2): The original Taiwanese study found both rs6837293 and rs7688672 associated with gout under a recessive model. These two intronic PRKG2 variants may be in linkage disequilibrium and tag the same underlying functional signal. Carriers of TT at both loci may represent the subgroup with the most consistent PRKG2-related risk signal.

The rs693 variant, known historically as the XbaI polymorphism, sits in exon 26 of the APOB gene¹¹ APOB gene
apolipoprotein B, the structural protein of LDL particles. Despite being a "silent" or synonymous mutation—the DNA change from C to T doesn't alter the amino acid (both code for threonine)—this variant has surprisingly robust effects on blood lipid levels and cardiovascular risk. It's a reminder that not all functional variants change protein sequence²² It's a reminder that not all functional variants change protein sequence
some affect mRNA stability, splicing efficiency, or are in linkage disequilibrium with truly causal variants.

The Mechanism

The rs693 SNP changes position 7673 in the APOB gene from cytosine (C) to thymine (T), creating a restriction site for the XbaI enzyme—hence its historical name. This transition occurs at codon 2488, changing ACC to ACT, but both encode threonine. Despite the synonymous nature, the A allele is consistently associated with elevated apolipoprotein B levels³³ Despite the synonymous nature, the A allele is consistently associated with elevated apolipoprotein B levels
the key structural protein in LDL, VLDL, and other atherogenic particles.

The mechanism likely involves effects on mRNA stability or translation efficiency rather than direct protein structure changes. ApoB is the main protein component of LDL particles⁴⁴ LDL particles
each LDL particle contains exactly one ApoB-100 molecule, making ApoB count a direct measure of atherogenic particle number. More ApoB means more LDL particles capable of infiltrating arterial walls and initiating atherosclerosis.

The Evidence

The evidence for rs693's cardiovascular impact is substantial. A 2017 meta-analysis of 61 studies including 50,018 subjects⁵⁵ 2017 meta-analysis of 61 studies including 50,018 subjects
showed A allele carriers had significantly higher ApoB levels (SMD 0.26), LDL-C (SMD 0.22), total cholesterol (SMD 0.24), and triglycerides (SMD 0.12). They also had slightly lower HDL-C (SMD -0.06).

In a Brazilian elderly cohort of 644 individuals⁶⁶ Brazilian elderly cohort of 644 individuals
AA homozygotes had mean LDL and total cholesterol levels about 10 mg/dL higher than CC or GA genotypes, with Cohen's d effect sizes of 0.35 for LDL. While 10 mg/dL may seem modest, population studies show that a 27 mg/dL increase in total cholesterol translates to 25-30% higher coronary disease incidence.

A meta-analysis specific to Han Chinese populations⁷⁷ meta-analysis specific to Han Chinese populations
analyzed 1,195 CHD patients and 1,178 controls, confirming the XbaI A allele confers significant CHD risk. The 2008 Malmö Diet and Cancer Study⁸⁸ 2008 Malmö Diet and Cancer Study
created a 9-SNP genotype score including rs693 that independently predicted 10-year cardiovascular events (MI, stroke, CHD death).

The A allele frequency varies dramatically by ancestry: 49-50% in Europeans, 38% in Africans and Latinos, 45% in South Asians, but only 2-10% in East Asians. This makes the variant particularly relevant for European-ancestry individuals, where roughly half the population carries at least one copy.

Practical Implications

If you're a T carrier (CT or AA genotype), your baseline lipid profile is likely shifted toward higher atherogenic particle counts. This doesn't guarantee cardiovascular disease— many factors contribute to risk—but it does mean your LDL particle number may be higher than LDL-C alone would suggest. ApoB directly measures particle number⁹⁹ ApoB directly measures particle number
and is increasingly recognized as superior to LDL-C for risk assessment when discordant.

Dietary response may differ by genotype. Saturated fat intake tends to raise LDL-C more in those genetically predisposed to higher ApoB production. Some evidence suggests T carriers benefit more from dietary modifications targeting particle number reduction: prioritizing monounsaturated fats, increasing soluble fiber, and limiting refined carbohydrates that drive VLDL and small dense LDL production.

Statin response can vary by APOB genotype, though rs693 itself has shown mixed results in pharmacogenetic studies. More important is ensuring treatment targets account for ApoB or non-HDL-C, not just LDL-C, if you're a T carrier—your particle number may be higher than cholesterol-based calculations suggest.

Interactions

The APOB rs693 variant interacts with other lipid-related SNPs to influence cardiovascular risk. The Kathiresan 9-SNP score¹⁰¹⁰ Kathiresan 9-SNP score
includes rs693 along with variants in APOE, LDLR, PCSK9, CETP, and other lipid genes, showing additive effects on LDL elevation and CVD risk. Those with multiple unfavorable alleles across these genes show progressively higher LDL and ApoB levels.

The related rs17240441 variant (a 9-bp insertion/deletion in APOB exon 1) also affects ApoB and lipid levels, with combined effects possible when both variants are present. Additionally, variants in MTHFR (like rs1801133) can interact with lipid metabolism through homocysteine pathways, potentially compounding cardiovascular risk in those with elevated ApoB.

Dietary gene-nutrient interactions are relevant: the effect of rs693 on lipid levels may be modified by saturated fat intake, omega-3 consumption, and overall dietary pattern. Some studies suggest Mediterranean-style diets may attenuate the lipid-raising effects of the A allele more effectively than high-saturated-fat Western diets.

Every adaptive immune response requires a second signal beyond antigen recognition. The OX40–OX40L axis¹¹ OX40–OX40L axis
OX40 (CD134) is a co-stimulatory receptor on activated T cells; its ligand OX40L (CD252) is expressed on antigen-presenting cells and provides the survival and proliferation signal that determines whether a T cell response is sustained or terminated is one of the most important of those second signals — controlling whether activated T cells survive, expand into effector cells, and help B cells mature into antibody-secreting plasma cells. TNFSF4, the gene encoding OX40 ligand (OX40L), sits on chromosome 1q25 and contains a regulatory upstream region that has been consistently implicated in systemic autoimmunity. rs7514229 is an intronic variant within TNFSF4 that tags this regulatory haplotype and has been linked to altered OX40L expression, autoimmune thyroid disease, and viral immune control.

The Mechanism

rs7514229 maps to an intronic position within TNFSF4 on chromosome 1 (GRCh38 chr1:173,185,165). TNFSF4 itself is transcribed from the minus strand, but dbSNP reports alleles on the plus strand — the reference allele is G, the alternate allele is T. As an intronic variant, rs7514229 does not change the OX40L amino acid sequence; instead, it serves as a tag for a broader upstream regulatory haplotype²² a broader upstream regulatory haplotype
Cunninghame Graham et al. Nature Genetics 2008 (PMID 18059267) identified four SNPs showing significant overtransmission in SLE families and demonstrated that susceptibility alleles were associated with a 6.7-fold increase in TNFSF4 transcript expression (P=0.008) in the TNFSF4 promoter region.

The functional consequence is altered OX40L surface expression. Higher OX40L on antigen-presenting cells strengthens OX40 signaling on T cells, promoting T cell survival beyond the normal timeframe, amplifying Th2-skewed responses, and providing excessive help to B cells in germinal centers — driving sustained antibody production, including autoantibodies. Bioinformatic analysis of the intronic rs7514229-T allele suggests it may also disrupt miRNA binding sites³³ miRNA binding sites
A regulatory mechanism by which microRNA molecules bind to complementary sequences in mRNA, typically in untranslated regions, to suppress gene expression, potentially further modulating TNFSF4 transcript stability or translation.

The Evidence

The foundational association between TNFSF4 and autoimmunity was established in a landmark 2008 Nature Genetics paper⁴⁴ landmark 2008 Nature Genetics paper
Cunninghame Graham et al. — two independent European SLE cohorts (UK WTCCC + US NIH), 36 SNPs across TNFSF4, four showing significant overtransmission; risk haplotype carriers showed 6.7-fold elevated TNFSF4 RNA expression in cells with susceptibility alleles that genotyped rs7514229 among 36 TNFSF4 variants and linked the upstream haplotype to SLE through elevated OX40L expression. This was subsequently replicated⁵⁵ replicated
Delgado-Vega et al. Genes & Immunity 2009 (PMID 19092840) — 1,312 cases, 1,801 controls; four European and Argentine cohorts; pooled OR=1.38–1.39 for the tagging haplotype across multiple European and Latin American populations.

Directly at rs7514229, a 2016 Chinese case-control study⁶⁶ 2016 Chinese case-control study
Song et al. Int J Mol Sci 2016 (PMID 27556446) — 1,048 AITD patients and 909 healthy controls, Han Chinese; four tagging SNPs in the TNFSF4 region found that the GG genotype at rs7514229 (homozygous reference, no T allele) was significantly associated with early-onset autoimmune thyroid disease (AITD) in patients aged ≤18 years. This population-specific finding, where G is the major allele in East Asians (~89%), points to a complex regulatory relationship in which the T/G haplotype context — rather than a simple additive dose — determines TNFSF4 expression thresholds relevant to thyroid autoimmunity during adolescent immune development.

A 2021 Chinese HCV study⁷⁷ 2021 Chinese HCV study
Fu et al. Frontiers in Genetics 2021 (PMID 33841497) — 3,690 participants including 2,309 uninfected controls, 597 spontaneous clearers, and 784 persistent HCV infection patients; false discovery rate corrected found rs7514229-T associated with increased HCV persistence risk. Individuals carrying multiple risk alleles (rs7514229-T plus rs3181366-T) showed a dose-dependent increase in infection susceptibility (P_trend<0.001), with bioinformatic evidence that T disrupts a miRNA binding site affecting TNFSF4 transcript regulation.

Practical Implications

OX40L/TNFSF4 operates at the interface of T cell survival and B cell help — two processes central to the autoimmune cycle. Carriers of rs7514229-T may have altered OX40L expression that shifts this balance toward sustained immune activation. The actionable response focuses on early recognition of autoimmune thyroid disease, one of the most common OX40L-linked conditions, and awareness of HCV risk in relevant contexts.

Autoimmune thyroid disease presents in two main forms: Graves' disease⁸⁸ Graves' disease
Autoimmune hyperthyroidism where TSH receptor autoantibodies stimulate thyroid hormone overproduction; characterized by weight loss, heat intolerance, palpitations, and sometimes exophthalmos (bulging eyes) and Hashimoto's thyroiditis⁹⁹ Hashimoto's thyroiditis
Autoimmune hypothyroidism where lymphocytic infiltration destroys thyroid tissue; characterized by fatigue, cold intolerance, weight gain, and goiter. Both are diagnosable with standard thyroid function tests (TSH, free T4, free T3) and thyroid autoantibodies (anti-TPO, anti-thyroglobulin, TSH receptor antibodies).

Interactions

TNFSF4 does not operate in isolation from the broader autoimmune susceptibility landscape. A gene-gene interaction study in Chinese SLE¹⁰¹⁰ gene-gene interaction study in Chinese SLE
Wang et al. 2011 (PMID 21905002) — multiplicative interaction model in 806 cases and 806 controls found a significant interaction between BLK rs2736340 and TNFSF4 in SLE susceptibility (P=6.57×10⁻⁴). BLK encodes a B-cell tyrosine kinase critical for self-tolerance; reduced BLK expression (from the rs2736340 risk allele) combined with elevated OX40L co-stimulation from the TNFSF4 risk haplotype creates a dual defect — impaired B cell tolerance plus amplified T cell help for autoreactive B cells. The nearby TNFSF4 variants rs2205960 and rs1234317 (from the SLE-associated haplotype) and rs3850641 (associated with Hashimoto's hypothyroidism) represent functionally overlapping signals within the same regulatory region that may compound with rs7514229 on the same haplotype.

Interleukin-13¹¹ Interleukin-13
IL-13 is a Th2 cytokine produced by mast cells, basophils, ILC2 innate lymphoid cells, and activated CD4+ helper T cells; it drives IgE class-switching in B cells, mucus hypersecretion in airway epithelium, airway smooth-muscle hyperresponsiveness, and suppression of epidermal barrier proteins including filaggrin is one of the most consequential mediators of allergic inflammation. At chromosome 5q31.1, a cluster of interrelated variants spans the IL13 gene and nearby regulatory elements, forming a haplotype block that has emerged as one of the strongest and most consistently replicated genetic loci in allergy genetics.

rs1295686 is an intronic variant within IL13 located at chr5:132,660,151 (GRCh38). It does not change the IL-13 protein sequence — its significance lies in the haplotype it marks. The minor T allele co-segregates tightly with rs20541 (the missense variant that produces the hyperactive Q130 form of IL-13) and rs1295685 (a 3'-UTR regulatory variant linked to enhanced mRNA stability). Together, these three variants — plus rs848 and rs847 — define the IL13 risk haplotype block at 5q31.1 that has been linked to atopic dermatitis, asthma, allergic rhinitis, elevated serum IgE, and IgE-mediated food allergy across dozens of independent studies.

The Mechanism

As an intronic variant, rs1295686 does not alter IL-13 protein function directly. Luciferase reporter and chromosome conformation capture experiments²² Luciferase reporter and chromosome conformation capture experiments
Li et al. Am J Respir Cell Mol Biol 2022 — identified functional SNPs at the locus as rs1295685, rs848, and rs847, which form a haplotype that interacts with the promoter of TH2LCRR, a long non-coding RNA with elevated expression in asthma patients show that the causal functional effect at this locus operates through a haplotype interacting with TH2LCRR — a long non-coding RNA elevated in asthmatic airways. rs1295686 lies in strong linkage disequilibrium with this functional haplotype and with rs20541, which changes amino acid 130 of the IL-13 protein from arginine (R, lower receptor affinity) to glutamine (Q, higher receptor engagement and enhanced signaling through IL-13Rα1).

When the T allele at rs1295686 is present, the carrier almost invariably also carries the rs20541-A (Q130) and rs1295685-A risk alleles. The combined effect of these co-inherited variants is higher constitutive IL-13 pathway activity: elevated circulating IL-13 protein with enhanced receptor engagement drives persistent IgE production in B cells, mucus hypersecretion and airway hyperresponsiveness in the lung, and epidermal barrier disruption through STAT6-mediated suppression of filaggrin and loricrin in the skin.

The Evidence

The 5q31.1 IL13/RAD50 locus is among the most robust signals in atopy genetics. A 2023 European and multi-ancestry GWAS meta-analysis³³ 2023 European and multi-ancestry GWAS meta-analysis
Budu-Aggrey et al. Nature Communications; ~21,000 cases and ~95,000 controls in European discovery, 2.9 million in 23andMe replication placed the IL13/SLC22A5 5q31 locus at P<10⁻³⁶ for atopic dermatitis — one of the most significant signals in human atopy genetics. rs1295686 lies within this haplotype block.

For food allergy specifically, a challenge-confirmed pediatric cohort study⁴⁴ challenge-confirmed pediatric cohort study
Ashley et al. Clin Exp Allergy 2017; discovery n=722 (367 food-allergic cases, 199 sensitized-tolerant, 156 controls) and replication n=533 (203 cases, 330 controls) found the T allele at rs1295686 associated with IgE-mediated food allergy at OR=1.75 (p=0.003) in discovery and OR=1.37 (p=0.03) in replication; the meta-analysis yielded OR=1.50 (p=0.0006). This study confirmed complete LD between rs1295686 and rs20541, establishing that the intronic tag and the coding functional variant travel together on the same risk haplotype.

For total serum IgE, a genome-wide association study in the Framingham Heart Study⁵⁵ genome-wide association study in the Framingham Heart Study
Granada et al. J Allergy Clin Immunol 2012; 6,819 Framingham participants plus 5 independent replication cohorts identified rs1295686 as one of three loci reaching genome-wide significance (P=3.55×10⁻⁸) for elevated total plasma IgE — alongside FCER1A (the high-affinity IgE receptor) and STAT6 (the primary IL-13 downstream transcription factor).

For asthma, analyses in Chinese pediatric and adult cohorts⁶⁶ Chinese pediatric and adult cohorts
Tang et al. Pediatr Allergy Immunol 2016; 903 asthmatic children, 1,205 controls; 479 adult asthmatics, 746 controls found rs1295686 associated with adult asthma (OR=1.64) and early-onset asthma (OR=1.92), confirming IL13 and GSDMB as replicated asthma genes. A study in Saudi Arabian adults⁷⁷ Saudi Arabian adults
Halwani et al. J Asthma 2018 found the T allele at rs1295686 conferred OR=1.69 (p=0.008) for symptomatic asthma, extending the association beyond European ancestry.

The African-ancestry T allele frequency is markedly higher (~66%) than in Europeans (~20%), reflecting population-specific LD patterns. This does not translate directly into higher atopic disease rates, as gene-environment interactions differ, but it does mean the risk allele is substantially more common in individuals of African descent — a factor relevant to genetic counseling in diverse populations.

Practical Implications

Carrying one or two copies of the T allele at rs1295686 indicates membership in the IL-13 high-activity haplotype. The practical consequence is a higher baseline Th2 bias: more IL-13 activity, higher IgE production, and increased susceptibility to the full atopic triad (eczema, allergic rhinitis, asthma) and IgE-mediated food allergy. Measuring serum total IgE quantifies how biologically active this IL-13 pathway is in the individual.

For those with active atopic disease inadequately controlled by topical or standard therapies, the IL-13/IL-4 pathway is the genetically-indicated target. IL-13-specific biologics (tralokinumab) and IL-4Rα inhibitors (dupilumab) directly neutralize the cytokine pathway this haplotype overactivates. Skin barrier protection with ceramide emollients addresses the downstream consequence — filaggrin suppression — of high IL-13 signaling.

Interactions

rs1295686 lies in near-complete linkage disequilibrium with rs20541⁸⁸ rs20541
IL-13 R130Q missense variant; Q130 form engages IL-13Rα1 with higher affinity, driving stronger JAK1/STAT6 signaling in B cells, airway epithelium, and skin keratinocytes and rs1295685⁹⁹ rs1295685
IL-13 3'-UTR variant affecting mRNA stability, on the same risk haplotype block. Carriers of the T allele at rs1295686 are thus almost invariably also carrying the rs20541-A and rs1295685-A risk alleles.

The downstream receptor partner for IL-13 signaling is IL-4Rα (encoded by IL4R, variant rs1801275). Carriers of both the IL-13 haplotype risk allele (rs1295686-T) and the IL4R risk allele may face compounding Th2 dysregulation — elevated IL-13 ligand activity meeting altered receptor signal transduction — with pharmacogenomic relevance to dupilumab response, which acts directly on the shared IL-4/IL-13 receptor subunit.

The upstream regulatory hub rs2040704 (in the RAD50/TH2LCRR region) coordinates expression of the IL-4/IL-5/IL-13 cytokine gene cluster. Combined risk allele status at both rs1295686 and rs2040704 may represent compounding Th2 amplification from different regulatory levels.

Inside every pancreatic beta cell, a molecular tug-of-war determines your fasting blood glucose set point. Glucokinase¹¹ Glucokinase
An enzyme that phosphorylates glucose to glucose-6-phosphate (G6P), initiating glycolysis and triggering insulin release acts as an accelerator, driving glucose into the glycolytic pathway. G6PC2 acts as the brake — it hydrolyzes G6P back into free glucose, creating a futile cycle that raises the glucose concentration required to trigger insulin secretion. The balance between these two enzymes defines the glucose-sensing threshold²² glucose-sensing threshold
The minimum blood glucose concentration that stimulates meaningful insulin release from beta cells — your personal fasting glucose set point.

rs1402837 sits 646 bp upstream of the G6PC2 transcription start site, in a region of open chromatin in human pancreatic islets. It is in very high linkage disequilibrium³³ linkage disequilibrium
LD r²=0.97, meaning the two variants are inherited together 97% of the time and tag the same underlying signal with the lead GWAS variant rs34177044. When the T allele disrupts regulatory element activity at this position, less G6PC2 is expressed in beta cells — the brake eases, glycolytic flux increases at lower glucose concentrations, and the fasting glucose set point shifts downward.

The Mechanism

G6PC2 is expressed almost exclusively in pancreatic islets, where it counteracts glucokinase by converting G6P back to glucose. This substrate futile cycle⁴⁴ futile cycle
A metabolic loop that dissipates energy without net product synthesis; here it makes the beta cell less sensitive to rising glucose raises the glucose level at which insulin secretion is triggered. Research from 2025 also showed that G6PC2 operates in alpha cells, where it defines the glucose concentration at which glucagon secretion is suppressed — linking the locus to both hormonal arms of glucose regulation. ⁵⁵ Bahl et al. 2025 Science Translational Medicine — G6PC2 controls glucagon set point in alpha cells; allele-specific expression confirmed at linked variants

The rs1402837 T allele falls in an open chromatin region detected by H3K4me3 ChIP-seq in human islets, consistent with a cis-regulatory role. It is one of several upstream variants (alongside intronic and promoter variants such as rs560887, rs573225, and rs2232316) that collectively modulate G6PC2 transcript abundance and, consequently, the fasting glucose set point.

The Evidence

The association between the G6PC2 locus and fasting glucose is one of the most strongly replicated signals in human metabolic genetics. rs1402837 specifically was identified in a genome-wide scan of HbA1c⁶⁶ genome-wide scan of HbA1c
Paré et al. 2008 — novel association of HK1 and G6PC2 loci with glycated haemoglobin in 14,618 non-diabetic women; rs1402837 p=6.8×10⁻¹⁰, explaining 0.2% of HbA1c variance in 14,618 apparently healthy Caucasian women. The variant is in very high LD with the fasting glucose lead signal rs34177044, which was replicated in 5,786 non-diabetic Chinese individuals at p=6.9×10⁻¹² (β=0.145 mmol/L per glucose-raising allele) ⁷⁷ Spracklen et al. 2018 PLoS Genetics — functional analysis of glycemic trait loci in the China Health and Nutrition Survey.

The broader G6PC2 locus has been studied in meta-analyses covering up to 187,968 non-diabetic participants, confirming that variants at this locus collectively explain approximately 1–2% of fasting glucose variance — a substantial fraction for common genetic variants. Importantly, the glucose-raising effect is seen without increased type 2 diabetes risk in most populations, consistent with G6PC2's role in setting the fasting setpoint rather than impairing overall glucose tolerance. ⁸⁸ Baerenwald et al. 2013 Diabetologia — multiple functional G6PC2 polymorphisms contribute additively to fasting plasma glucose elevation

The gene is also expressed in alpha cells, where it regulates glucagon suppression threshold. Recent functional studies showed that G6pc2 deletion in alpha cells improves glucose-mediated glucagon suppression, pointing to a bihormonal mechanism and a potential therapeutic target for pharmacological inhibition.

Practical Actions

The T allele at rs1402837 lowers the fasting glucose set point through reduced G6PC2 expression. Carriers benefit from an inherently lower fasting glucose baseline that requires no intervention. For those with the common CC genotype — where both copies of the C reference allele maintain full G6PC2 expression — the glucose set point sits higher. While this is not pathological, it represents a quantifiable contribution to lifetime glycemic load. The most actionable lever for CC carriers is limiting dietary inputs that directly challenge the already-higher fasting glucose threshold: refined carbohydrates and high-glycemic foods raise postprandial glucose spikes that interact with the elevated set point. Spreading carbohydrate intake across smaller, more frequent meals — rather than large boluses — reduces peak beta-cell demand. Regular aerobic activity independently lowers the fasting glucose set point through AMPK-mediated pathways that do not involve G6PC2.

Interactions

The G6PC2 fasting glucose signal is additive with variants in glucokinase (GCK, rs1799884) and the glucokinase regulatory protein gene (GCKR, rs1260326), which operate on the same beta-cell glucose-sensing pathway from the opposite direction. Individuals carrying glucose-raising alleles at both G6PC2 and GCK show compounded effects on fasting glucose and insulin secretion capacity. The combined risk allele score across G6PC2, GCK, GCKR, and MTNR1B variants is associated with meaningful fasting glucose elevation and increased type 2 diabetes risk. ⁹⁹ Li et al. 2009 Diabetes — additive effects of GCK and G6PC2 variants on insulin secretion and fasting glucose (BetaGene + METSIM cohorts)

Every CD58 intronic variant associated with multiple sclerosis risk — rs2300747, rs12044852, rs1016140, rs1335532 — sits within the same tightly linked haplotype block in the first intron of CD58 on chromosome 1. Among them, rs1414273 holds a mechanistically unique position¹¹ rs1414273 holds a mechanistically unique position
rs1414273 lies directly within the hairpin sequence of hsa-miR-548ac, the microRNA co-encoded from the same primary transcript as CD58 mRNA: it is the functional anchor through which the risk haplotype disrupts the balance between CD58 and an immunoregulatory microRNA.

CD58, also known as LFA-3 (Lymphocyte Function-Associated Antigen 3)²² LFA-3 (Lymphocyte Function-Associated Antigen 3)
LFA-3 is a glycoprotein expressed on antigen-presenting cells and non-immune tissues; it binds CD2 on T cells to stabilise the immune synapse and transmit co-stimulatory signals that licence regulatory T cell induction, governs whether a T-cell encounter with an antigen-presenting cell produces immune tolerance or inflammatory activation. This signalling axis sits at the centre of multiple sclerosis genetics: the CD58 locus is one of the most robustly replicated non-HLA MS susceptibility regions.

The Mechanism

The miR-548ac gene is embedded within CD58 intron 1. Like all microRNAs, it begins as part of a longer primary transcript (pri-miRNA) that is cropped by the nuclear Drosha-DGCR8 endonuclease complex³³ Drosha-DGCR8 endonuclease complex
Drosha cleaves the pri-miRNA at the base of the hairpin stem-loop to release the 60–70 nt precursor (pre-miRNA), which is then exported to the cytoplasm and processed by Dicer into the mature ~22 nt miRNA. Because CD58 mRNA and miR-548ac are transcribed from the same genomic locus, Drosha cleavage efficiency has a reciprocal effect: more efficient cleavage favours miR-548ac production at the expense of full-length CD58 mRNA reaching the cytoplasm for translation.

rs1414273 sits at the precise base of the miR-548ac stem-loop. The reference allele is C on the plus strand — corresponding to G on the coding (minus) strand — which pairs with a uridine in the opposite strand of the hairpin to form a G-U wobble base pair. The alternate T allele (coding-strand A) forms an A-U Watson-Crick base pair, which is less efficiently recognised by Drosha. The consequence:

• C allele (risk): G-U wobble → enhanced Drosha recognition → more miR-548ac, less CD58 mRNA
• T allele (protective): A-U Watson-Crick → reduced Drosha efficiency → less miR-548ac, more CD58 mRNA

In cell-culture experiments, the G-containing construct (risk allele) produced 1.5-fold more mature miR-548ac at 24 hours and 3.4-fold more at 48 hours compared to the A-containing construct, after normalisation to precursor RNA. In population-level eQTL analyses spanning HapMap, Geuvadis, and MS patient cohorts, risk allele carriers showed significantly lower CD58 transcript levels and significantly higher miR-548ac levels⁴⁴ risk allele carriers showed significantly lower CD58 transcript levels and significantly higher miR-548ac levels
The paradoxical inverse relationship between CD58 mRNA and miR-548ac co-encoded from the same locus is explained by Drosha-mediated uncoupling: cleavage of the stem-loop interrupts full-length mRNA synthesis while liberating the microRNA hairpin.

miR-548ac targets validated in this mechanistic framework include SDC4 (syndecan-4)⁵⁵ SDC4 (syndecan-4)
SDC4 regulates T-cell motility and heparan sulfate proteoglycan signalling, SEL1L⁶⁶ SEL1L
SEL1L participates in endoplasmic reticulum-associated protein degradation (ERAD) and proteostasis under inflammatory stress, and TNFAIP3 (A20)⁷⁷ TNFAIP3 (A20)
TNFAIP3/A20 is a master ubiquitin-editing enzyme that terminates NF-κB signalling; miR-548ac-mediated suppression of A20 would sustain inflammatory NF-κB activity. A broader computational screen identified 333 predicted miR-548ac targets enriched in cytokine signalling, MAPK pathways, and protein folding — consistent with a broadly immunomodulatory role for this microRNA.

The Evidence

The functional significance of rs1414273 was first proposed by Galarza-Munoz et al. 2015⁸⁸ Galarza-Munoz et al. 2015
1000 Genomes sequencing data used to identify rs1414273 as the only SNP at the base of the miR-548ac stem-loop in strong LD with the MS-associated haplotype, who recognised that its position within the Drosha recognition element made it a strong candidate for the causal variant within the CD58 MS locus.

The full mechanistic and eQTL evidence was published by Hecker et al. 2019 PLoS Genetics⁹⁹ Hecker et al. 2019 PLoS Genetics
Expression QTL analysis across >1,000 subjects from HapMap and Geuvadis cohorts combined with in vitro Drosha cleavage experiments and real-time PCR of 32 MS patients. This study demonstrated both the population-level expression effects and the molecular mechanism in a single unified study, making rs1414273 the best-characterised functional variant at the CD58 MS locus.

The variant is in near-complete LD (r² ≈ 1, D' ≈ 1) with rs1335532, the GWAS lead SNP for the CD58 MS locus in European cohorts. Correlated alleles on the forward strand are: rs1414273 C = rs1335532 A (both risk alleles); rs1414273 T = rs1335532 C (both protective alleles). This tight LD means rs1414273 and rs1335532 are functionally interchangeable for GWAS-level MS association signals, but rs1414273 uniquely maps the molecular effect to Drosha recognition.

Population genetics provide an instructive layer. The C (risk) allele is the major allele in Europeans (~87%) — matching the high-frequency risk pattern seen throughout the CD58 locus (rs12044852, rs2300747). In contrast, East Asian and African populations carry the T (protective) allele at ~59% and ~51% respectively. This mirrors the population-level MS burden: the disease is considerably rarer in East Asian populations where the protective T allele predominates.

A pilot replication study in a Malaysian/Kuwaiti cohort found CD58 rs1414273 to be significantly associated with MS in an Arab population (p = 0.00007, OR 2.2, 95% CI 1.5–3.2 in exome analysis), though a separate genotyping-only Kuwaiti replication did not reach significance, likely reflecting population-specific LD structure between rs1414273 and the GWAS signals.

Practical Actions

Since the C allele is the major allele in Europeans (~87%), CC homozygotes represent the largest fraction of the population — and carry the highest miR-548ac burden and lowest CD58 expression at this locus. There is no supplement that directly inhibits miR-548ac or compensates for reduced CD58, but vitamin D is the best-characterised modifiable factor that supports FoxP3+ regulatory T cell function¹⁰¹⁰ FoxP3+ regulatory T cell function
FoxP3 is the master transcription factor for Tregs; vitamin D drives FoxP3 expression via VDR binding at the FoxP3 promoter, providing a parallel Treg-supporting input to the CD58 co-stimulatory signal through mechanisms independent of CD58.

Interactions

rs1414273 is in near-complete LD with rs1335532 and is strongly correlated with rs12044852 (r² = 0.929 between rs12044852 and rs2300747, with rs1414273 in the same haplotype). The four CD58 intronic variants — rs2300747, rs12044852, rs1016140, rs1414273 — collectively define the CD58 MS-risk haplotype. The rs1016140 G allele has an independent signal for NMO risk and autoimmune thyroid disease via a mechanistically distinct direction, illustrating that the intronic haplotype block contains variants with both shared and divergent functional effects.

miR-548ac's validated target TNFAIP3 (A20) connects this variant to the NF-κB inflammatory pathway, creating a potential interaction with cytokine-pathway SNPs (e.g. TNFRSF1A rs1800693 in the same immune-gut category).

The vitamin D receptor (VDR) is a nuclear receptor ¹¹ A nuclear receptor is a protein that binds hormones or vitamins inside the cell and directly regulates gene expression that mediates the biological effects of vitamin D throughout your body. When active vitamin D (calcitriol) ²² Calcitriol (1,25-dihydroxyvitamin D) is the hormonally active form of vitamin D binds to VDR, it triggers gene expression changes that affect calcium absorption, immune function, cell growth, and hundreds of other processes. VDR is expressed in nearly every tissue in the body, which is why vitamin D affects so many aspects of health.

The Mechanism

The BsmI variant (rs1544410) is located in an intronic region of the VDR gene. While it does not directly change the protein sequence, it is in linkage disequilibrium ³³ Linkage disequilibrium: nearby genetic variants that are inherited together more often than expected by chance with functional variants that affect VDR mRNA stability and expression levels. The T allele is associated with reduced VDR expression, meaning your cells produce fewer vitamin D receptors and are therefore less responsive to circulating vitamin D. The variant frequency varies dramatically by ancestry — 40% in Europeans but only 6% in East Asians.

The Evidence

A meta-analysis of 26 studies⁴⁴ meta-analysis of 26 studies
Tao S et al. VDR BsmI polymorphism and osteoporosis risk, 2012 and a larger 42-study meta-analysis⁵⁵ larger 42-study meta-analysis
Zhao L et al. VDR BsmI and osteoporosis in postmenopausal women, 2020 found that VDR BsmI variants are associated with osteoporosis susceptibility in Caucasians (OR 0.70 for bb vs BB), bone mineral density, and calcium absorption efficiency. The associations are strongest in populations with lower baseline vitamin D levels. Additional research has linked VDR variants to immune function, autoimmune disease risk, and cancer susceptibility, though these associations are more complex and context-dependent.

The Vitamin D Optimization Challenge

VDR variants create a situation where standard blood levels of vitamin D may not produce standard biological effects. If your cells have fewer vitamin D receptors, you may need higher circulating vitamin D levels to achieve the same cellular response as someone with normal VDR expression. This is why some people with "adequate" blood levels still seem to benefit from higher vitamin D intake.

Practical Implications

If you carry the T allele, maintaining vitamin D levels in the optimal range (30-50 ng/mL) is important, and you may benefit from aiming toward the higher end of that range. Regular testing (1-2 times per year) helps you calibrate your supplementation. Vitamin D3 is preferred over D2, and taking it with a fat-containing meal improves absorption.

Interactions

VDR interacts with CYP2R1 (rs10741657) — if both vitamin D activation and receptor sensitivity are impaired, the combined "double hit" significantly impacts vitamin D status.

Adiponectin is your body's master metabolic regulator¹¹ regulator
a hormone secreted by fat tissue that enhances insulin sensitivity, reduces inflammation, and protects against metabolic disease, and the ADIPOQ gene controls how much of it you produce. The rs17300539 variant sits in the gene's promoter region — the control switch that determines transcription activity²² transcription activity
how actively the gene is read and translated into protein. What makes this variant fascinating is its paradoxical effects: the A allele cranks up adiponectin production, yet doesn't always deliver the metabolic protection you'd expect.

Normally, higher adiponectin is protective — it improves insulin sensitivity, lowers inflammation, reduces cardiovascular risk, and guards against type 2 diabetes. People with obesity and metabolic syndrome typically have low adiponectin levels³³ low adiponectin levels
adiponectin secretion is impaired in obesity, creating a vicious cycle of worsening insulin resistance, which contributes to their disease. Yet your genotype at rs17300539 introduces a twist: some people produce more adiponectin but still face elevated metabolic risk.

The Mechanism

The rs17300539 SNP is a G-to-A substitution at position -11391 in the ADIPOQ promoter region. In vitro studies⁴⁴ In vitro studies
laboratory experiments using cell cultures demonstrate that the A allele significantly increases transcriptional activity compared to the G allele, driving higher adiponectin production. The variant likely alters transcription factor binding⁵⁵ transcription factor binding
proteins that attach to DNA and regulate gene expression at this promoter site, though the exact factors involved haven't been fully mapped.

Adiponectin circulates in your blood in three forms: low molecular weight (LMW) trimers, medium molecular weight (MMW) hexamers, and high molecular weight (HMW) multimers⁶⁶ low molecular weight (LMW) trimers, medium molecular weight (MMW) hexamers, and high molecular weight (HMW) multimers. The HMW form is the most biologically active — it's the one that enhances insulin sensitivity⁷⁷ enhances insulin sensitivity
stimulates AMPK activation in muscle and liver, increasing glucose uptake and fatty acid oxidation and delivers cardiovascular protection. Some evidence suggests that rs17300539 may influence the ratio of HMW to total adiponectin⁸⁸ ratio of HMW to total adiponectin, which could explain why total adiponectin levels don't always predict metabolic outcomes in carriers.

The Evidence

The Framingham Offspring Study⁹⁹ Framingham Offspring Study
a landmark cardiovascular epidemiology study following multiple generations genotyped 2,543 participants and found that the A allele at rs17300539 showed the strongest association with higher adiponectin levels (P = 2.6 × 10⁻⁸). Each A allele added roughly 1.6 μg/mL to circulating adiponectin. This finding has been replicated across multiple populations — European, Asian, and Latino cohorts all show the same pattern.

But here's the paradox: a 2009 study in obese children¹⁰¹⁰ a 2009 study in obese children
1,210 Greek children aged 9-13, both obese and non-obese found that A-allele carriers (GA+AA) had higher adiponectin levels but also higher BMI (B = 0.97, P = 0.015) and a 35% increased odds of obesity (OR = 1.35, 95% CI 1.06-1.85). Before adjusting for obesity status, they showed higher fasting insulin and higher HOMA-IR (a measure of insulin resistance). The researchers concluded that "the rs17300539-A variant, though consistently associated with higher adiponectin levels, does not exert any appreciable protective metabolic effect in children."

In adults, the story differs by baseline metabolic health. A 2023 study in 329 obese Caucasian adults¹¹¹¹ A 2023 study in 329 obese Caucasian adults
Spanish cohort with mean BMI 47.8 kg/m² found that GG homozygotes had significantly higher rates of metabolic syndrome (86% vs. 73.9%, P < 0.05), hypertriglyceridemia, hyperglycemia, and insulin resistance (HOMA-IR 7.49 vs. 4.62) compared to A-allele carriers. GG carriers also had lower adiponectin levels (4.27 vs. 6.36 μg/mL). Logistic regression confirmed that the GG genotype independently increased metabolic syndrome risk (OR = 2.52, 95% CI 1.04-6.10) even after adjusting for age, sex, weight, and dietary intake.

The variant also shows strong association with polycystic ovary syndrome (PCOS)¹²¹² strong association with polycystic ovary syndrome (PCOS) in Chinese populations — a family-based transmission disequilibrium test in 197 PCOS families confirmed overtransmission of the risk allele. PCOS is fundamentally a condition of insulin resistance and hyperandrogenism, often accompanied by low adiponectin.

A meta-analysis of 35 studies¹³¹³ A meta-analysis of 35 studies
nearly 29,000 participants across multiple ethnicities linked rs17300539 to coronary artery disease (CAD) risk, though effect sizes varied by population and the direction wasn't always consistent — likely reflecting the complex interplay between adiponectin levels, HMW ratio, and other metabolic factors.

Practical Actions

The clearest clinical implication emerges from the bariatric surgery literature¹⁴¹⁴ bariatric surgery literature: A-allele carriers show better lipid profile improvements after surgery. In 60 extremely obese individuals followed for 32 months post-surgery, those with the A-C haplotype (combining rs17300539-A with rs266729-C) had greater reductions in LDL cholesterol. This suggests that in the context of major metabolic intervention — whether bariatric surgery or intensive lifestyle modification — the A allele's adiponectin-boosting effect finally translates into benefit.

The gene-diet interaction studies¹⁵¹⁵ gene-diet interaction studies are particularly relevant. In the RISCK study, rs17300539 genotype interacted significantly with dietary fat composition to determine adiponectin levels. Another study in the GOLDN cohort¹⁶¹⁶ Another study in the GOLDN cohort found that the association between the -11391A allele and lower BMI was modified by monounsaturated fatty acid (MUFA) intake — A-allele carriers who consumed higher MUFA had the lowest BMI and obesity risk.

Fish oil supplementation may be particularly relevant: omega-3 fatty acids activate PPARγ¹⁷¹⁷ omega-3 fatty acids activate PPARγ, which upregulates adiponectin expression, and one study found that ADIPOQ genotype modified the response to fish oil supplementation in older individuals.

Interactions

The ADIPOQ gene sits at the intersection of several metabolic pathways. Adiponectin signals through two receptors — AdipoR1¹⁸¹⁸ AdipoR1
predominantly expressed in skeletal muscle, activates AMPK pathways and AdipoR2¹⁹¹⁹ AdipoR2
predominantly in liver, activates PPARα signaling. The downstream effects include increased fatty acid oxidation, reduced hepatic glucose production, and improved insulin sensitivity.

Three other common ADIPOQ SNPs show linkage disequilibrium with rs17300539: rs266729 (-11377C>G, also in the promoter, r² = 0.80 with rs17300539), rs2241766 (+45T>G in exon 2, also called Gly15Gly), and rs1501299 (+276G>T in intron 2). These variants may compound or modify effects, particularly regarding the HMW adiponectin ratio. Haplotype analysis sometimes reveals stronger associations than single SNPs alone.

There's emerging evidence for interaction with TCF7L2 variants²⁰²⁰ TCF7L2 variants, the strongest type 2 diabetes risk gene. TCF7L2 regulates adipocyte development and function, and deletion of TCF7L2 in adipocytes impairs glucose tolerance and alters lipid metabolism. The combination of ADIPOQ and TCF7L2 risk variants may identify individuals who benefit most from dietary fat modification.

Finally, the obesity paradox deserves emphasis: if you're lean and metabolically healthy, higher adiponectin from the A allele is likely beneficial. But if you're already obese or insulin-resistant, the A allele may signal a compensatory response — your body is pumping out more adiponectin to counteract metabolic dysfunction, but it's not enough to overcome the underlying problem. In that scenario, the GG genotype's association with lower adiponectin may simply reflect better baseline metabolic health.

FABP2 (Fatty Acid Binding Protein 2) is expressed in intestinal cells and is responsible for intracellular transport of dietary fatty acids¹¹ Inside enterocytes (intestinal absorptive cells), FABP2 shuttles fatty acids from the cell membrane to the endoplasmic reticulum for processing.

The Mechanism

The Ala54Thr variant (rs1799883) is a missense mutation in exon 2 of FABP2, where an adenine replaces guanine at the DNA level, substituting alanine with threonine at position 54 of the protein (p.Ala54Thr). Baier et al.²² Baier et al.
Baier et al. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J Biol Chem, 1995 demonstrated that the threonine-containing protein has a 2-fold greater affinity for long-chain fatty acids than the alanine-containing protein, leading to more efficient fat absorption from the intestine.

The Evidence

The original discovery by Baier et al.³³ original discovery by Baier et al.
Baier et al. J Biol Chem, 1995 in Pima Indians showed that Thr54 carriers had higher fasting insulin, lower insulin-stimulated glucose uptake, and higher fat oxidation rates. The threonine variant increases the protein's affinity for long-chain fatty acids by approximately 2-fold.

Carriers of the Thr allele absorb more calories from fat⁴⁴ Studies estimate Thr carriers may absorb roughly 20-30% more long-chain fatty acids per meal than Ala/Ala individuals, which can contribute to weight gain when fat intake is high.

A meta-analysis by Zhao et al.⁵⁵ meta-analysis by Zhao et al.
Zhao et al. Association between FABP2 Ala54Thr polymorphisms and T2DM risk: a HuGE review and meta-analysis. Lipids Health Dis, 2014 found significant associations with type 2 diabetes in Asian populations (OR 1.19, 95% CI 1.05-1.36) but not in Caucasians. The evidence for obesity association is mixed, with some meta-analyses finding no significant effect on BMI.

Practical Implications

The Thr allele is common across all populations (24-33% frequency), with slightly higher frequency in South Asian and East Asian groups. The practical significance is moderate — this variant matters most when combined with high dietary fat intake, where increased absorption efficiency can contribute to excess calorie intake and insulin resistance.

Interactions

FABP2 Ala54Thr interacts with total dietary fat intake — the variant's metabolic effects are more pronounced on high-fat diets. If you also carry TCF7L2 risk alleles (rs7903146), moderating fat intake becomes doubly important.

TPMT (thiopurine S-methyltransferase) is the enzyme that inactivates thiopurine drugs¹¹ inactivates thiopurine drugs
Azathioprine, 6-mercaptopurine, and thioguanine — used for inflammatory bowel disease, autoimmune conditions, organ transplantation, and childhood leukemia maintenance by methylating them to inert metabolites. When TPMT activity is reduced or absent, these drugs are diverted into a pathway that generates highly toxic thioguanine nucleotides, which incorporate into DNA and cause life-threatening bone marrow suppression at standard doses. TPMT*2 (rs1800462) was the first TPMT deficiency allele ever identified — described by Krynetski and colleagues in 1995 — and it remains one of the four clinically relevant no-function star alleles tested before thiopurine prescription. Unlike the *3 cluster (*3A, *3B, *3C), which dominates TPMT deficiency in Europeans, *2 is a completely independent functional allele on its own chromosomal background and is the rarer of the two European no-function variant classes.

The Mechanism

TPMT*2 is a single-nucleotide substitution at position 238 of the TPMT coding sequence (c.238G>C) that changes alanine 80 to proline²² alanine 80 to proline
p.Ala80Pro — proline introduces a rigid kink into the protein backbone, disrupting local secondary structure near the SAM-binding pocket in the methyltransferase domain. TPMT is on the minus strand of chromosome 6, so the coding-strand c.238G>C mutation corresponds to a plus-strand C→G substitution at chr6:18143724 (GRCh38). Functional studies by Tai and colleagues³³ Tai and colleagues
Tai HL et al. Enhanced proteasomal degradation of mutant TPMT (TPMT*3A and TPMT*2) in humans. PNAS 1997 showed that the Ala80Pro substitution destabilizes the folded protein, marks it for ubiquitin-dependent degradation⁴⁴ ubiquitin-dependent degradation
The mutant enzyme has a half-life roughly 15-fold shorter than wild-type TPMT, with near-complete turnover via the 26S proteasome, and leaves cells with essentially no functional TPMT from the 2 allele. In vitro, TPMT*2 retains only about 1% of wild-type catalytic activity — roughly a **100-fold reduction* — making it functionally equivalent to the *3A and *3C no-function alleles for clinical purposes.

The Evidence

TPMT is the most thoroughly characterised pharmacogene in clinical practice. The CPIC thiopurine dosing guideline⁵⁵ CPIC thiopurine dosing guideline
Clinical Pharmacogenetics Implementation Consortium — Level A evidence, the highest tier for clinical implementation has been published since 2011 and updated multiple times since. Every CPIC version classifies TPMT*2 as a no-function allele with activity score 0, functionally identical to *3A, *3B, and *3C for dosing purposes. The original 2011 guideline⁶⁶ original 2011 guideline
Relling MV et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011 named *2, *3A, *3B, and *3C as the four variant alleles that should be tested in routine clinical practice — a panel that remains standard. The 2018 update⁷⁷ 2018 update
Relling MV et al. CPIC Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther 2019 extended the framework to NUDT15 (the dominant thiopurine safety gene in East Asians) and refined the dose-reduction recommendations. The original molecular identification of TPMT*2⁸⁸ molecular identification of TPMT*2
Krynetski EY et al. A single point mutation leading to loss of catalytic activity in human thiopurine S-methyltransferase. Proc Natl Acad Sci USA 1995 came from cloning and sequencing TPMT cDNA from a TPMT-deficient patient who had experienced severe myelosuppression on 6-mercaptopurine. Population studies⁹⁹ Population studies
Otterness DM et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997 place the TPMT*2 allele frequency at roughly 0.2-0.5% in Europeans, making it 5-10 times less common than the *3A haplotype but still responsible for a measurable fraction of TPMT-deficient individuals of European ancestry. TPMT*2 is essentially absent in East Asian and South Asian populations, where NUDT15 variants (rs116855232 in particular) are the dominant cause of thiopurine toxicity. The FDA includes TPMT status in its pharmacogenomic biomarker table¹⁰¹⁰ pharmacogenomic biomarker table for azathioprine, mercaptopurine, and thioguanine, with package inserts explicitly recommending pre-treatment genotyping.

Practical Implications

If you carry one or two copies of TPMT*2, you are at risk for severe thiopurine-induced bone marrow suppression at standard doses — the same clinical risk carried by people with TPMT*3A/3B/*3C variants. European populations carry the *2 variant at roughly 0.2-0.5% allele frequency, meaning about 1 in 200-400 people of European ancestry is heterozygous (one functional TPMT allele from the *2), and homozygous *2/*2 is extremely rare. The CPIC 2025 guideline recommends starting at 30-80% of the standard dose for intermediate metabolizers (one no-function allele of any type) and 10% of the standard dose or an alternative medication for poor metabolizers (two no-function alleles — whether *2/*2, *2/*3A, *2/*3C, or any other combination). Because TPMT deficiency classification depends on **all variant alleles in combination*, anyone found to carry *2 must also be genotyped for *3B (rs1800460), *3C (rs1142345), and NUDT15 (rs116855232) to determine the complete metabolizer phenotype. Missing a second variant on the other chromosome is the classic way that a compound heterozygous poor metabolizer gets labeled as an intermediate metabolizer and receives a dangerous dose.

Interactions

The most clinically important interaction for TPMT*2 is with other TPMT no-function alleles in trans (on the opposite chromosome). TPMT*2 is on a completely different chromosomal background from the 3 cluster — it is NOT part of the *3A haplotype — which means someone carrying *2 plus *3A in trans, or *2 plus *3B alone, or *2 plus *3C alone, is a **compound heterozygous poor metabolizer* with essentially zero TPMT activity and the same dosing requirements as a *3A/*3A homozygote (10% of standard dose or thiopurine avoidance entirely). Clinical labs distinguish *2 carriers by direct genotyping at rs1800462¹¹¹¹ direct genotyping at rs1800462
Most commercial TPMT panels test *2, *3A, *3B, and *3C simultaneously — but some older panels or raw-data imports may miss *2 entirely, which is why this rsid must be part of any TPMT pharmacogenomic pipeline. If your genome file shows rs1800462(G) combined with rs1142345(C) or rs1800460(T), your prescriber should treat you as a poor metabolizer until haplotype phasing confirms otherwise.

A second critical interaction is with NUDT15 (rs116855232), the other thiopurine safety gene. NUDT15 loss-of-function variants act on a downstream step of thiopurine metabolism, and individuals carrying variants in both TPMT and NUDT15 require larger dose reductions than predicted by either gene alone. Both genes should always be checked together before thiopurine prescription. Finally, co-administration of allopurinol¹²¹² allopurinol
Xanthine oxidase inhibitor used for gout; blocks an alternate thiopurine inactivation pathway or febuxostat with thiopurines creates a double-blockade that is particularly dangerous in TPMT variant carriers — the FDA label instructs reducing azathioprine to 25% of the standard dose when combined with allopurinol, and that reduction must be applied on top of any TPMT-based dose reduction.